EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

New Insights Into an Old Vaccine: Potency and Breadth of Neutralizing Antibodies Elicited by Yellow Fever Vaccine 17D Are Boosted by Heterologous Orthoflavivirus Infection

Felicity J Coulter iD, Courtney A Micheletti iD, Abram E Estrada iD, Shuhua Luo iD, Samantha R Osman iD, Chad D Nix iD, Sophia Y Hu, Sarah M Sampouw iD, Bettie W Kareko, Allison L Naleway, William B Messer iD

The Journal of Infectious Diseases · 02.09.2026 · 234 (2) · e232-e242

DOI: 10.1093/infdis/jiag077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 11.02.2026. Verfasst von Felicity J Coulter und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Yellow Fever Vaccine, Antibodies, Viral, Yellow fever virus. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCATS NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Yellow fever vaccine 17D has controlled yellow fever for almost 90 years and is considered highly successful. However, with recent outbreaks in South America and Africa, yellow fever continues to represent a significant threat to public and global health. Despite the long-standing success, few studies have characterized the capacity of 17D-immune sera to neutralize wild type (WT) yellow fever viruses (YFVs).

Methods

Using 17D and 13 WT YFVs, we conducted focus neutralization tests against sera from a unique cohort of 36 nonendemic vaccinees with diverse Orthoflavivirus histories. By using WT YFVs that represent the known YFV genotypes, we characterized the potency and breadth of 17D-elicited serum neutralizing antibodies against these WT YFVs in the context of heterologous Orthoflavivirus infection.

Results

We found significant variability in neutralization test titers and rates of seropositivity of 17D-immune sera across all viruses and specifically against South America genotype I isolates. Vaccinee sera with serologic evidence of heterologous Orthoflavivirus infection had significantly greater potency against South America genotype I strains as compared with sera without evidence of Orthoflavivirus infection, suggesting a boosting effect from heterologous Orthoflavivirus immunity.

Conclusions

These results add significantly to what is known regarding the WT YFV antigenic immune landscape, including novel insights into the role of heterologous Orthoflavivirus infection in 17D immunity that have the potential to improve future vaccine design and deployment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, NeutralizingYellow Fever VaccineAntibodies, ViralYellow fever virusYellow FeverHumansNeutralization TestsSouth AmericaGenotypeFemale

Stichwörter der Autor:innen

Orthoflavivirus17Dneutralizing antibodiesyellow fever virus

Substanzen

Antibodies, NeutralizingYellow Fever VaccineAntibodies, Viral

Autor:innen und Institutionen

  • Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, USA.
  • Kaiser Permanente Center for Health Research, Portland, Oregon, USA.
  • Division of Infectious Diseases, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
  • Program in Epidemiology, Oregon Health & Science University-Portland State University School of Public Health, Portland, Oregon, USA.

ORCID-Profile: Felicity J Coulter, Courtney A Micheletti, Abram E Estrada, Shuhua Luo, Samantha R Osman, Chad D Nix, Sarah M Sampouw, William B Messer

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS
  • NIH

Zitieren

APA

Coulter, F. J., Micheletti, C. A., Estrada, A. E., Luo, S., Osman, S. R., Nix, C. D., Hu, S. Y., Sampouw, S. M., Kareko, B. W., Naleway, A. L., & Messer, W. B. (2026). New Insights Into an Old Vaccine: Potency and Breadth of Neutralizing Antibodies Elicited by Yellow Fever Vaccine 17D Are Boosted by Heterologous Orthoflavivirus Infection. The Journal of Infectious Diseases, 234(2), e232-e242. https://doi.org/10.1093/infdis/jiag077

Vancouver

Coulter FJ, Micheletti CA, Estrada AE, Luo S, Osman SR, Nix CD, et al. New Insights Into an Old Vaccine: Potency and Breadth of Neutralizing Antibodies Elicited by Yellow Fever Vaccine 17D Are Boosted by Heterologous Orthoflavivirus Infection. The Journal of Infectious Diseases. 2026;234(2):e232-e242. doi:10.1093/infdis/jiag077

BibTeX
@article{Coulter2026,
  author = {Coulter, Felicity J and Micheletti, Courtney A and Estrada, Abram E and Luo, Shuhua and Osman, Samantha R and Nix, Chad D and Hu, Sophia Y and Sampouw, Sarah M and Kareko, Bettie W and Naleway, Allison L and Messer, William B},
  title = {New Insights Into an Old Vaccine: Potency and Breadth of Neutralizing Antibodies Elicited by Yellow Fever Vaccine 17D Are Boosted by Heterologous Orthoflavivirus Infection},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  volume = {234},
  number = {2},
  pages = {e232--e242},
  doi = {10.1093/infdis/jiag077}
}
Kostenlos starten →